Osteopore Ltd
ASX:OSX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Osteopore Ltd
ASX:OSX
|
3.4m AUD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
56.1B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
28.8B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
95.5B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.4B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
39.4B CNY |
Loading...
|
|
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
38.8B CNY |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
836.8B JPY |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Osteopore Ltd
Glance View
Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic and maxillofacial surgeries. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-09-23. The firm is engaged in commercializing a range of products to facilitate bone healing across multiple therapeutic areas. The company fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material using its platform technology. Its 3D print scaffold design is based on the principle of tissue engineering and regenerative medicine. Its craniofacial products include Osteomesh, Osteoplug, and Osteoplug-C. Its craniofacial products are used as bone void fillers for regeneration of natural bone. The company also develops and manufactures implants that focuses on unmet clinical needs which improve patient outcomes. Its science of tissue engineering and regenerative medicine provides various surgical solutions for medical surgeons. Its products are used by surgeons across Asia, Europe, Australia, and the Americas.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Osteopore Ltd is 77.5%, which is below its 3-year median of 77.7%.
Over the last 3 years, Osteopore Ltd’s Gross Margin has increased from 75.2% to 77.5%. During this period, it reached a low of 70.1% on Jun 30, 2023 and a high of 83.5% on Jun 30, 2024.
